Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 304 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HPV Infections Clear all

Conditions: HPV, Vaccine-Preventable Diseases
Interventions: vaccination game; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 11 Years to 14 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chandler, Arizona

Conditions: Neoplasms
Interventions: Curcumin, Placebo; Drug
Lead sponsor: Lisa Flowers; Other
Eligibility: 21 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: HIV Positive, Anal Condylomata, Anal Warts, HIV Infections
Interventions: Saline, Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
Interventions: Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis; Device · Biological · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 7
States / cities: San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 4 more

Conditions: Adolescent HPV Vaccine, Adolescent Influenza Vaccine
Interventions: 4 Pillars Toolkit; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 11 Years to 17 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Infections, Papillomavirus, Papillomavirus Vaccines
Interventions: GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM), Gardasil ® (Merck & Co. Inc), Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 40
States / cities: Chandler, Arizona • San Diego, California • San Francisco, California + 36 more

Conditions: Papillomavirus Infections
Interventions: human papillomavirus vaccine L1, type 6,11,16,18; Biological
Lead sponsor: Eisenhower Army Medical Center; Federal
Eligibility: 18 Years to 26 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Fort Gordon, Georgia

Conditions: Immunization, HPV Infection, Human Papillomavirus
Interventions: 9-valent HPV vaccine, 2 doses alternate timing, 9-valent HPV vaccine, 3 doses standard timing; Biological
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 27 Years to 45 Years · Female only
Enrollment: 618 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Recurrent Respiratory Papillomatosis, Papillomavirus Infections, Papillomaviridae
Interventions: PRGN-2012 - Phase I; Dose Level 1, PRGN-2012 - Phase I; Dose Level 2, PRGN-2012 - Phase II; Dose Level 2; Drug
Lead sponsor: Precigen, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer Survivor, Prevention of Human Papillomavirus Infection
Interventions: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58), laboratory biomarker analysis, survey administration, medical chart review; Biological · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 9 Years to 26 Years
Enrollment: 1,499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 5
States / cities: Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 2 more

Conditions: Genital Human Papilloma Virus Infection
Interventions: Gardasil; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 26 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Carcinoma, Oropharyngeal Squamous Cell Carcinoma (OPSCC), Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma (SCC), Oropharyngeal Squamous Cell Carcinoma (OPSCCA), Oropharyngeal Cancer, Oropharyngeal Squamous Cell Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma, HPV 16 Positive Oropharyngeal Tumors (OPC)
Interventions: Dose de-escalation to contralateral neck., Dose de-escalation to gross disease to contralateral neck, Dose de-escalation to gross disease, Circulating Tumor DNA test (ctDNA test); Radiation · Diagnostic Test
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 4
States / cities: Baltimore, Maryland • Columbia, Maryland • Glen Burnie, Maryland

Conditions: Warts
Interventions: Resiquimod; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 10
States / cities: Jonesboro, Arkansas • San Francisco, California • Longmont, Colorado + 7 more

Conditions: Infections, Papillomavirus, Papillomavirus Vaccines
Interventions: Cervarix, Placebo control; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 26 Years and older · Female only
Enrollment: 5,752 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2014
U.S. locations: 36
States / cities: Fountain Valley, California • Aurora, Colorado • Golden, Colorado + 29 more

Conditions: Common Warts
Interventions: DFD05 Cream, Active01 Cream; Drug
Lead sponsor: Dr. Reddys Laboratories, SA, Switzerland; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 12
States / cities: Hot Springs, Arkansas • Fremont, California • Sacramento, California + 9 more

Conditions: Anal Cancer, Nonneoplastic Condition, Penile Cancer, Precancerous Condition
Interventions: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, laboratory biomarker analysis; Biological · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 13 Years to 26 Years · Male only
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 18
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 10 more

Conditions: Human Papillomavirus Infection, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma
Interventions: Docetaxel, Hyperfractionation, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment; Drug · Radiation · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Human Papillomavirus
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 100 Years
Enrollment: 850 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2047
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV/AIDS, Cervical Dysplasia, HIV Infections
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Anal Cancer, Neoplasm of Uncertain Malignant Potential, Nonneoplastic Condition, Precancerous Condition
Interventions: clinical observation, infrared photocoagulation therapy; Other · Device
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 27 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more

Conditions: External Genital Warts
Interventions: Investigational Treatment, Aldara; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Arlington Heights, Illinois

Conditions: Warts, HPV
Interventions: Candida Antigen; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Common Wart
Interventions: Active, Vehicle; Drug · Other
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 24
States / cities: Glendale, Arizona • Fort Smith, Arkansas • Encinitas, California + 21 more

Conditions: Warts
Interventions: Resiquimod; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 10
States / cities: Fayetteville, Arkansas • Little Rock, Arkansas • Newnan, Georgia + 7 more

Search by objective public record fields.

Playing Game to Learn About Children's Vaccine Project

Topical Curcumin for Precancer Cervical Lesions

The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

4 Pillars Toolkit for Adolescent Vaccination

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities

Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis

Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study

A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)

Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts

Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer

Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)

Factors Predicting Persistence of Oncogenic HPV and Cervical Dysplasia in HIV Infected Kenyan Women

Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

Study With Candida Antigen for Treatment of Warts

A Study of A-101 Topical Solution for the Treatment of Common Warts

An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects